Cowealth Medical Holding Co Ltd

Cowealth Medical's capital structure is characterized by a debt-to-equity ratio of 0.18, indicating a relatively low reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 2.79, suggesting it can cover short-term obligations but with limited excess cash. However, the company's cash and equivalents of TWD 56.99 million are significantly lower than its long-term debt of TWD 519.71 million, resulting in a negative net cash position. Profitability metrics show a challenging performance, with a return on equity (ROE) of -8.59% and a return on assets (ROA) of -3.5%, both well below the industry median for Advanced Medical Equipment & Technology. The company reported a net loss of TWD 246.56 million and an operating loss of TWD 275.21 million, indicating operational inefficiencies or declining demand. The company's revenue is concentrated in China, as disclosed in its primary distribution strategy, though specific geographic breakdowns are not provided in the input data. The lack of segment-level revenue data limits the ability to assess geographic diversification or product line performance. Growth trajectory appears negative, with no outlook data provided for the current or next fiscal year. The company's free cash flow is negative at TWD -295.72 million, and capital expenditures of TWD -14.69 million suggest limited reinvestment in growth. The absence of positive revenue growth signals in the financial history indicates a potential contraction in operations. Risk factors include a medium liquidity risk due to the negative net cash position and a low dilution risk, as shares outstanding remain unchanged between basic and diluted counts. No dilution adjustments are applied in the custom valuations, and no recent equity issuance is disclosed in the input data. Recent events are not detailed in the input data, but the company's financial performance in the latest period suggests operational challenges. The absence of positive earnings or cash flow generation may prompt scrutiny from investors and creditors, though no specific filings or transcripts are cited in the input.